Track topics on Twitter Track topics that are important to you
210, 1167 Kensington Crescent
AB T2N 1X7
Phone: (403) 670-7377
Fax: (403) 283-0858
Dr. Rita Laeufle, M.D., Ph.D., had been working as a consultant for Oncolytics for the last four months
On Monday (September 10), Oncolytics Biotech (NASDAQ:ONCY, TSX:ONC) announced details of its new collaboration for its Phase 3 clinical trial. The post New Collaboration For Oncolytics Biotech and SOL...
Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a clinical col...
Oncolytics Biotech Inc, currently developing Reolysin (pelareorep), an intravenously delivered immuno─oncolytic virus turning cold tumours hot, announced a clinical collaboration with SOLTI, an acad...
CALGARY, Alberta and SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic vir...
Oncolytics Biotech (NASDAQ:ONCY,TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the execution of a Common Stock P...
CALGARY, Alberta and SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic v...
- Webcast and conference call for investors and analystson Thursday, September 20 at 8:30 a.m. EDT - CALGARY, Alberta and SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (...
Anticancer peptides (ACPs) are cationic amphiphiles that preferentially kill cancer cells through folding-dependent membrane disruption. Although ACPs represent attractive therapeutic candidates, part...
The long-term goal of this research is to apply technologic approaches to improve the use of oral oncolytics. The objective of this study is to assess patient adherence to oral oncolytics ...
Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. Oncolytics has completed five clinical trials...
The Company's technologies are based on discoveries arising from research conducted at the University of Calgary. Dr. Coffey, VP Product Development for the Company was instrumental in these discoveri...
We have published hundreds of Oncolytics news stories on BioPortfolio along with dozens of Oncolytics Clinical Trials and PubMed Articles about Oncolytics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oncolytics Companies in our database. You can also find out about relevant Oncolytics Drugs and Medications on this site too.